
The panel considers how AI and automation could reshape peptide method development, and why scientific judgment will remain essential.
This article describes the current situation in FDA-regulated areas, as well as characterization of these products. Finally,the author discusses the various stages of early- and late-phase product developments.
over 20 years ago
Analytical Instrument Qualificationover 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?over 20 years ago
Team Effortover 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedover 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionover 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressover 20 years ago
New Climateover 20 years ago
2006: A Regulatory Odyssey



